Post-Closure Local Anesthetic

PreclinicalSmall molecule

Post-Closure Local Anesthetic is one of 5 small molecule programs targeting Local Anesthetic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Local AnestheticUnknown status

Local AnestheticPreclinical

Unknown status

Competition

Competitive Landscape

8 competitors in Local Anesthetic

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

1 2

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Phase 2

2 3

Phenol

NNorthwestern University

Preclinical

1 4

Alkalinized Lidocaine

MMassachusetts General Hospital

Preclinical

1 5

Post-Closure Local Anesthetic

VValley Anesthesiology Consultants

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Local Anesthetic1 trial

Evaluation of Local Anesthetic at Incision Site

Unknown status·VValley Anesthesiology Consultants·N/A·NCT02483689·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Post-Closure Local Anesthetic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Post-Closure Local Anesthetic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Post-Closure Local Anesthetic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valley Anesthesiology Consultants company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VValley Anesthesiology Consultants

Post-Closure Local Anesthetic

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Local Anesthetic1 trial

References

Drug Info

Quick Facts

Related News